Allergan (NYSE:AGN) CEO David Pyott has described himself as a "mountaineer," a "born marketer," and a bit of a masochist, but there’s 1 thing the man undoubtedly is: A pioneer of the medical technology world.
MassDevice Big 100
One way to assess stock values is to compare the stock’s share price with its asset value.
The latter is the number of shares outstanding divided into total assets. When the result is compared with share prices, it can help investors decide whether a stock is over- or under-valued.
We took a look at the asset values for 15 of the world’s largest pure-play medical device companies and then compared them with the companies’ stock price.
The economic recovery has been slow going in the U.S. as the housing market and persistently high unemployment have proven particularly stubborn.
That’s why we were surprised, after looking at the employment numbers in our MassDevice Big 100 database, to find that only 3 of the largest 15 med-tech makers wound up cutting their global workforces last year.
We’re looking at debt-to-equity ratios, which measure how aggressively a company finances its growth using debt. It’s an important metric, especially during rough economic patches, because highly leveraged companies run the risk of not generating enough growth to outweigh the cost of the debt – which could lead to bankruptcy.
Here’s a look at the 5 highest debt ratios among the pure-play medical device companies on our Big 100 list:
The current economic downturn has put paid to the notion that healthcare markets are recession-proof, with the formerly high-flying medical device industry struggling along with the rest of the business world.
But for some companies, the bad economy proved less of an impediment to profitability than for other, last year in particular.
More than $50 billion was spent on acquisitions by Big 100 medical device companies from the beginning of 2011 through the 1st half of 2012.
MassDevice held its 2nd annual Big 100 Roundtable East event in Waltham, Mass., July 10. A group of nearly 250 med-tech executives and stakeholders gathered for an evening of networking, insight into medical device marketing and intimate interviews with Michael Mahoney (incoming CEO of Boston Scientific), Abiomed CEO Michael Minogue and GI Dynamics CEO Stuart Randle.
MassDevice.com is proud to announce an exceptional lineup of medical device leaders for the MassDevice Big 100 Regional Roundtable East on July 10, 2012, in Waltham, Mass.
The Big 100 Roundtable is a conversation among leaders – an unforgettable exchange of insight, ideas and contacts with the most prominent pioneers in our field.
MassDevice.com is proud to announce the MassDevice Big 100 Regional Roundtable West, an event slated for Dec. 12, 2011, in Irvine, Calif., recognizing cutting-edge leadership and innovation in the medical device field in southern California.